Efficacy and safety of a new inactivated vaccine against the rabbit haemorrhagic disease virus 2-like variant (RHDV-2)
Efficacy and safety of a new inactivated vaccine against the rabbit haemorrhagic disease virus 2-like variant (RHDV-2)
In 2010 a new variant of rabbit haemorrhagic disease (RHDV-2) emerged in France and quickly spread through several European countries, causing atypical outbreaks in commercial rabbitries. Classical RHDV vaccines showed low cross-protection against RHDV-2, revealing the need for a specific vaccine against the disease. In this study the efficacy and safety of ERAVAC, an inactivated vaccine developed by HIPRA for preventing RHDV-2, was evaluated and compared with its simultaneous administration with a classical RHDV vaccine (Cunipravac RHD).
